Evaluate the Continued Safety and Performance of the Foot and Ankle Products
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Products listed in Group/Cohort Description.
- Who it may be relevant to
- Registry conditions: Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle. Basic parameters: from 2 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, Germany, South Africa
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Performance of the Foot and Ankle Products
Overview
The objective of the registry is to evaluate the continued safety and performance of Arthrex foot and ankle products, including the ProStop® implant for hyperpronated foot; Bio-Compression Screw for reconstruction surgeries of the foot; TRIM-IT Drill Pin® system and/or TRIM-IT Spin Pin™ system for fixation of fractures and fusion (bunionectomy osteotomies) of the foot/ankle; Headless Compression Screws and Compression FT Screws for fixation of small bone fragments of the foot/ankle; DynaNite® nitinol staple for midfoot and hindfoot arthrodeses or osteotomies, first metatarsophalangeal arthrodesis, and mono or bi-cortical osteotomies in the forefoot; BioComposite SutureTak® anchor for medial ankle stabilization; Beveled FT Screws for hallux valgus repair; KreuLock™ screws for ankle fractures; ArthroFLEX® dermal allograft for hallux rigidus arthroplasty; and DualCompression Hindfoot Nail for tibiotalocalcaneal arthrodesis.
Detailed description
Device-related adverse events will be continuously assessed and summarized at three months, six months, one year, and two years postoperatively to evaluate safety. A physical exam of the target area will be conducted three months postoperatively to evaluate performance. Range of motion (ROM) will be assessed preoperatively, at three months, six months, and one year postoperatively for the ArthroFLEX® dermal allograft only. Patient-reported outcomes (PROs) will be evaluated for all products at three months, six months, and one year. Additionally, PROs will be assessed at two years postoperatively for ArthroFLEX® dermal allograft and DualCompression Hindfoot Nail only. PROs include the Foot and Ankle Ability Measures (FAAM), Visual Analogue Scale (VAS), Single Assessment Numeric Evaluation (SANE) score, and Veterans Rand 12-Item Health Survey (VR-12). DualCompression X-rays will be evaluated at six months and one year postoperatively for ArthroFLEX® dermal allograft and DualCompression Hindfoot Nail only, and CT scans will be assessed at three months postoperatively for DualCompression Hindfoot Nail only.
Interventions
- Device Products listed in Group/Cohort Description
Depending on approved indication per product
Primary outcome measures
- To assess change in Visual Analogue Scale (VAS) survey [Time frame: preoperatively, 3 months, 6 months and 12 months post operative]
- To assess changes in Veterans RAND Health (VR-12) survey [Time frame: preoperatively, 3 months, 6 months and 12 months post operative]
- To assess changes in Foot and Ankle Ability Measures (FAAM) survey [Time frame: preoperatively, 3 months, 6 months and 12 months post operative]
- To assess change in Single Assessment Numeric Evaluation (SANE) survey [Time frame: preoperatively, 3 months, 6 months and 12 months post operative]
Eligibility criteria
Inclusion criteria
- Subject requires surgery using Arthrex foot and ankle products included in the registry.
- Subject is 18 years of age or over (all products except ProStop®).
- Subject age >two to 17 years (ProStop® product only).
- Capable of completing self-administered questionnaires.
- Willing and able to return for all study-related follow-up visits.
- Subject or subject's representative signed informed consent and assent, when applicable, and is willing and able to comply with all study requirements.
(ArthroFLEX® subjects only):
- Degenerative or post-traumatic arthritis of the 1st MTP joint with grade 2, 3, or 4.
- Subjects who require surgical intervention or are medically indicated for an arthrodesis or arthroplasty of the 1st MTP.
DualCompression Hindfoot Nail subjects only:
- The participant must have instability, arthritis, rigid deformity, or severe foot or ankle deformity necessitating tibiotalocalcaneal arthrodesis, commonly referred to as TTC arthrodesis.
- The participant should be undergoing treatment with the Arthrex DualCompression Hindfoot Nail, either as a primary procedure or as a revision surgery, per standard of care
Exclusion criteria
- Insufficient quantity or quality of bone.
- Blood supply limitations and previous infections, which may retard healing.
- Foreign-body sensitivity.
- Any active infection or blood supply limitations.
- Conditions that tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period.
- Subjects that are skeletally immature (except for ProStop®).
- Subject is considered from vulnerable population (i.e., child, prisoner, pregnant).
- Subjects who are contraindicated for these devices.
- Subject is currently receiving compensation or benefits due to a work-related injury or illness under any applicable occupational injury or disability program.
- Subject has a planned or scheduled additional surgery on the affected or contralateral lower extremity within the course of the study.
(® Nitinol Staple Subjects only):
- Subjects who have a comminuted bone surface that would not allow for staple placement as required by the DynaNite® Nitinol Staples directions for use.
- Subjects who have pathologic bone conditions such as osteopenia that would impair the ability to securely fix the implant as required by the DynaNite® Nitinol Staples directions for use.
(ArthroFLEX® subjects only):
- Additional ipsilateral lower limb pathology that requires active treatment.
- Bilateral degenerative or post-traumatic arthritis of the 1st MTP joints that would require simultaneous treatment of both MTP joints.
- Diagnosis of gout.
- Any significant bone loss, avascular necrosis, and/or large osteochondral cyst (>1cm) of the 1st MTP joint.
- Lesions greater than 10mm in size.
- Hallux varus to any degree, or hallux valgus >20 degrees.
(DualCompression Hindfoot Nail subjects only):
- Requiring only a tibiotalar or subtalar arthrodesis
- Patient requires bulk allograft or metal spacer implant to fill large bony defect and aid in limb salvage
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-only
Study locations
United States · 5 centers
- UC Davis Medical Center — Sacramento
- Northwestern University — Chicago
- TOA Research Foundation — Nashville
- Barrett Podiatry — San Antonio
- Atlantic Orthopaedic Specialists — Virginia Beach
Germany · 1 center
- OrthoPedes — Duisburg
South Africa · 1 center
- Dr Haroun Mahomed Orthopaedic Practice — Durban
Identifiers
NCT: NCT04715139 · AIRR-0006